✦ LIBER ✦

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

✍ Scribed by Hanfstein, B; Shlyakhto, V; Lauseker, M; Hehlmann, R; Saussele, S; Dietz, C; Erben, P; Fabarius, A; Proetel, U; Schnittger, S; Krause, S W; Schubert, J; Einsele, H; Hänel, M; Dengler, J; Falge, C; Kanz, L; Neubauer, A; Kneba, M; Stegelmann, F; Pfreundschuh, M; Waller, C F; Spiekermann, K; Baerlocher, G M; Pfirrmann, M; Hasford, J; Hofmann, W-K; Hochhaus, A; Müller, M C

Book ID: 125807251
Publisher: Nature Publishing Group
Year: 2014
Tongue: English
Weight: 599 KB
Volume: 28
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2014.153

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quantitative molecular monitoring of BCR

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

✍ Sara Galimberti; Giulia Cervetti; Francesca Guerrini; Rossana Testi; Simone Paci 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 293 KB

Impact of BCR-ABL mutations on response

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

✍ Mario Tiribelli, Roberto Latagliata, Luigiana Luciano… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 143 KB

A report of early cytogenetic response t

A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript

✍ Xiaoqing Li; Jing Yang; Xiangjun Chen; Jun Liu; Hongrui Li; Jine Zheng; Yanli He 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 429 KB

Early reduction of BCR-ABL mRNA transcri

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

✍ Merx, K; Müller, M C; Kreil, S; Lahaye, T; Paschka, P; Schoch, C; Weisser, A; Ku 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 147 KB

Emerging kinetics of BCR–ABL1 mutations

Emerging kinetics of BCR–ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure

✍ Lee-Yung Shih; Ming-Chung Kuo; Ching-Yuan Kuo; Tseng-Hsi Lin; Li-Yaun Bai; Tsai- 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 743 KB

Early landmark analysis of imatinib trea

Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome

✍ Lotta Ohm; Ingrid Arvidsson; Gisela Barbany; Robert Hast; Leif Stenke 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 914 KB